Changes to Director Roles and Responsibilities

Summary by AI ^BETAClose X

Oxford Nanopore Technologies plc announced that effective July 1, 2026, Chief Financial Officer Nick Keher will assume additional responsibilities for Manufacturing, Supply Chain, Quality Assurance, Regulatory Affairs, and Operations, following the retirement of Chief Operating Officer Tim Cowper on June 30, 2026. This consolidation of key operational and financial oversight under one executive could streamline decision-making and potentially impact operational efficiency.

Disclaimer*

Oxford Nanopore Technologies plc

30 June 2026

Oxford Nanopore Technologies plc

(the "Company") 

Changes to Director Roles and Responsibilities

In accordance with UK Listing Rule 6.4.6R, the Company announces that, with effect from 1 July 2026, Nick Keher, Chief Financial Officer, will, in addition to retaining his existing responsibilities, assume responsibility for the Manufacturing, Supply Chain, Quality Assurance, Regulatory Affairs and Operations functions following the retirement of Tim Cowper, Chief Operating Officer, on 30 June 2026.

-ENDS-

For further information, please contact:

Oxford Nanopore Technologies plc

Investors: ir@nanoporetech.com

Media: media@nanoporetech.com

Teneo (communications adviser to the Company)

Tom Murray and Lisa Jarrett-Kerr

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for faster, information rich, accessible and affordable molecular analysis. The first application is DNA/RNA sequencing, and the technology is in development for the analysis of other types of molecules including proteins. The technology is used in more than 125 countries to understand and characterise the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes. For more, visit: www.nanoporetech.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END